Abstract
Introduction: The effectiveness and tolerability of triple therapy, which combines regorafenib, a programmed death 1 (PD-1) inhibitor, and transarterial chemoembolization (TACE), were compared to dual therapy consisting of regorafenib and a PD-1 inhibitor in patients with advanced hepatocellular carcinoma (HCC). Methods: A retrospective analysis was conducted on patients with advanced HCC who underwent second-line therapy from March 2019 to June 2022 at multiple centers. Patients were stratified into two groups: dual therapy (comprising regorafenib and a PD-1 inhibitor) and triple therapy (consisting of regorafenib, a PD-1 inhibitor, and TACE). Propensity score matching (PSM) was used to control for potential confounding variables. Results: After PSM, 112 eligible patients were included, with 56 in the triple therapy group and 56 in the dual therapy group. Median overall survival (OS) was significantly longer in the triple therapy group (15.4 vs. 8.9 months, p < 0.001), as was median progression-free survival (6.8 vs. 3.3 months, p < 0.001). The objective response rate (37.5% vs. 5.4%, p < 0.001) and disease control rate (73.2% vs. 44.6%, p = 0.002) were significantly higher in the triple therapy group compared to the dual therapy group. The incidence and severity of adverse events were similar between the two groups. Conclusion: Triple therapy demonstrated superior survival benefits compared to dual therapy in patients with advanced HCC. Additionally, the safety profiles of the two treatment regimens were comparable.
Journal Section:
Clinical Study
References
1.
Sung
H
, Ferlay
J
, Siegel
RL
, Laversanne
M
, Soerjomataram
I
, Jemal
A
, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
. CA Cancer J Clin
. 2021
;71
(3
):209
–49
. 2.
Marrero
JA
, Kulik
LM
, Sirlin
CB
, Zhu
AX
, Finn
RS
, Abecassis
MM
, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases
. Hepatology
. 2018
;68
(2
):723
–50
. 3.
Llovet
JM
, Ricci
S
, Mazzaferro
V
, Hilgard
P
, Gane
E
, Blanc
J-F
, et al. Sorafenib in advanced hepatocellular carcinoma
. N Engl J Med
. 2008
;359
(4
):378
–90
. 4.
Kudo
M
, Finn
RS
, Qin
S
, Han
K-H
, Ikeda
K
, Piscaglia
F
, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
. Lancet
. 2018
;391
(10126
):1163
–73
. 5.
Qin
S
, Bi
F
, Gu
S
, Bai
Y
, Chen
Z
, Wang
Z
, et al. Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase II-III trial
. J Clin Oncol
. 2021
;39
(27
):3002
–11
. 6.
Chung
GE
, Lee
J-H
, Kim
HY
, Hwang
SY
, Kim
JS
, Chung
JW
, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival
. Radiology
. 2011
;258
(2
):627
–34
. 7.
Kudo
M
, Ueshima
K
, Ikeda
M
, Torimura
T
, Tanabe
N
, Aikata
H
, et al. Randomised, multicentre prospective trial of Transarterial Chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
. Gut
. 2020
;69
(8
):1492
–501
. 8.
Fu
Z
, Li
X
, Zhong
J
, Chen
X
, Cao
K
, Ding
N
, et al. Lenvatinib in combination with transarterial chemoembolization for treatment of Unresectable Hepatocellular Carcinoma (uHCC): a retrospective controlled study
. Hepatol Int
. 2021
;15
(3
):663
–75
. 9.
He
X
, Xu
C
. Immune checkpoint signaling and cancer immunotherapy
. Cell Res
. 2020
;30
(8
):660
–9
. 10.
El-Khoueiry
AB
, Sangro
B
, Yau
T
, Crocenzi
TS
, Kudo
M
, Hsu
C
, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
. Lancet
. 2017
;389
(10088
):2492
–502
. 11.
Zhu
AX
, Finn
RS
, Edeline
J
, Cattan
S
, Ogasawara
S
, Palmer
D
, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
. Lancet Oncol
. 2018
;19
(7
):940
–52
. 12.
Finn
RS
, Qin
S
, Ikeda
M
, Galle
PR
, Ducreux
M
, Kim
T-Y
, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
. N Engl J Med
. 2020
;382
(20
):1894
–905
. 13.
Ren
Z
, Xu
J
, Bai
Y
, Xu
A
, Cang
S
, Du
C
, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
. Lancet Oncol
. 2021
;22
(7
):977
–90
. 14.
Xin
Y
, Zhang
X
, Liu
N
, Peng
G
, Huang
X
, Cao
X
, et al. Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma
. Hepatol Int
. 2023
;17
(3
):753
–64
. 15.
Duan
X
, Li
H
, Kuang
D
, Chen
P
, Zhang
K
, Li
Y
, et al. Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study
. Hepatol Int
. 2023
;17
(4
):915
–26
. 16.
Pathak
S
, Sonbol
MB
. Second-line treatment options for hepatocellular carcinoma: current landscape and future direction
. J Hepatocell Carcinoma
. 2021
;8
:1147
–58
. 17.
Zou
X
, Xu
Q
, You
R
, Yin
G
. Efficacy and safety of TACE combined with regorafenib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma after sorafenib resistance
. J Hepatocell Carcinoma
. 2023
;10
:267
–79
. 18.
Yang
X
, Deng
H
, Sun
Y
, Zhang
Y
, Lu
Y
, Xu
G
, et al. Efficacy and safety of regorafenib plus immune checkpoint inhibitors with or without TACE as a second-line treatment for advanced hepatocellular carcinoma: a propensity score matching analysis
. J Hepatocell Carcinoma
. 2023
;10
:303
–13
. 19.
Li
Z
, Li
L
, Zhong
J
, Cui
K
, Zhang
C
, Shi
X
, et al. Regorafenib combined with PD-1 monoclonal antibody in the second-line setting for Hepatocellular Carcinoma (HCC): a retrospective, real-world study in China
. J Clin Oncol
. 2022
;40
(16_Suppl l
):e16145
. 20.
Tischfield
DJ
, Gurevich
A
, Johnson
O
, Gatmaytan
I
, Nadolski
GJ
, Soulen
MC
, et al. Transarterial embolization modulates the immune response within target and nontarget hepatocellular carcinomas in a rat model
. Radiology
. 2022
;303
(1
):215
–25
. 21.
Huinen
ZR
, Huijbers
EJ
, van Beijnum
JR
, Nowak-Sliwinska
P
, Griffioen
AW
. Anti-angiogenic agents—overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
. Nat Rev Clin Oncol
. 2021
;18
(8
):527
–40
. 22.
Teufel
M
, Seidel
H
, Köchert
K
, Meinhardt
G
, Finn
RS
, Llovet
JM
, et al. Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma
. Gastroenterology
. 2019
;156
(6
):1731
–41
. 23.
Abou-Elkacem
L
, Arns
S
, Brix
G
, Gremse
F
, Zopf
D
, Kiessling
F
, et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model
. Mol Cancer Ther
. 2013
;12
(7
):1322
–31
. 24.
Giannone
G
, Ghisoni
E
, Genta
S
, Scotto
G
, Tuninetti
V
, Turinetto
M
, et al. Immuno-metabolism and microenvironment in cancer: key players for immunotherapy
. Int J Mol Sci
. 2020
;21
(12
):4414
. 25.
Liu
J
, Tao
H
, Yuan
T
, Li
J
, Li
J
, Liang
H
, et al. Immunomodulatory effects of regorafenib: enhancing the efficacy of anti-PD-1/PD-L1 therapy
. Front Immunol
. 2022
;13
:992611
. 26.
Fidelman
N
. A Leap from TACE to TACE potentiated by immune response modulation and angiogenesis inhibition for patients with intermediate-stage hepatocellular carcinoma: LEAP-012 phase 3 randomized control trial protocol
. Cardiovasc Intervent Radiol
. 2022
;45
(4
):413
–4
. 27.
Bruix
J
, Qin
S
, Merle
P
, Granito
A
, Huang
Y-H
, Bodoky
G
, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
. Lancet
. 2017
;389
(10064
):56
–66
. 28.
Yan
T
, Peng
C
, Yu
L
, Duan
X
, Ji
D
, Zhang
L
, et al. A retrospective study on the efficacy and safety of regorafenib or regorafenib combined with immune-checkpoint-inhibitors (ICIs) after first-line therapy in patients with advanced hepatocellular carcinoma
. J Clin Oncol
. 2022
;40
(16_Suppl l
):e16115
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
